Archive for category: Special Report

In early September 2026, logistics technology company Descartes acquired Extensiv, a provider of warehouse-management and fulfillment technology for third-party logistics providers, for approximately $120 million. Descartes framed the deal as expanding its warehouse and inventory capabilities and connecting them more closely with its existing transportation management, shipment visibility, trade intelligence, customs compliance, and last-mile tools. It followed the company’s August acquisition of a transportation-management provider.

This is not a pharmaceutical deal, and there is no reason to treat it as one. But it is a clear signal of a broader trend in the logistics industry, one that matters a great deal for regulated products: warehouse operations, transportation, and customs data are increasingly being connected into a single technology ecosystem. The industry is investing heavily to make these functions speak to each other, because the value of connecting them has become obvious.

For regulated products, connected data is not a convenience. It is a compliance requirement. A GMP warehouse cannot operate as an information island, because the questions regulators and clients ask about a pharmaceutical shipment cross the boundaries between warehouse, transportation, and customs.

Why Information Islands Fail Regulated Products

Consider a simple question a client or a regulator might ask about a specific pharmaceutical shipment: did this lot remain within its required temperature range from the moment it cleared customs until it shipped to the customer? Answering that question requires customs data (when did it clear), warehouse data (when was it received, where was it stored, what was its release status), monitoring data (was there any excursion), and shipment data (when did it leave, where did it go). If those four data sets live in separate systems that do not connect, assembling the answer is slow, manual, and error-prone, and in a regulated industry, an answer that is slow and manual is a liability.

When warehouse, transportation, and customs data are disconnected, the failures are predictable. The warehouse does not know a shipment is held at customs until it fails to arrive. Customer service cannot see whether product is released or quarantined. Customs has product data that does not match what is physically in the warehouse. An excursion event is recorded in one system but not linked to the lots it affected. Each of these is a gap where compliance can break down and where a client’s confidence erodes.

The connected alternative is straightforward to describe, even if it takes real work to build. The warehouse knows every shipment’s customs status. Operations know whether product is released or quarantined. Customer service sees accurate inventory and shipment status. Customs has product data that matches reality. And exception information, a hold, an excursion, a delay, flows across the whole chain so that everyone who needs to act on it can. The functions tell the same story because they draw on the same data.

Ten Data Domains That Should Tell One Story

A genuinely connected 3PL operation aligns a specific set of data domains so that warehouse, transportation, customs, and customer-facing functions all work from consistent information. For regulated products, these ten are the ones that matter most.

The point is not that each of these data domains exists somewhere. In most operations they do. The point is whether they connect, whether the HTS classification the customs team uses matches the master product data the warehouse works from, whether the release status the quality team sets is the same status customer service sees, whether an excursion event is linked to the specific lot and shipment it touched. Connection is what turns ten separate records into one coherent story about a product.

The Connections That Matter Most for Regulated Product

Product Data, Classification, and What Is Physically Stored

Master product data, HTS classification, and warehouse inventory have to describe the same thing. When the customs entry classifies a product one way and the warehouse holds it under a different description or specification, the mismatch is exactly the kind of discrepancy a CBP or FDA review surfaces. Connected data means the definition of the product is consistent from the customs entry through the warehouse shelf.

Customs Status and Warehouse Receiving

The link between customs entry status and warehouse operations is one of the highest-value connections for imported regulated product. When the warehouse can see that a shipment is cleared, held, or pending, it can plan receiving, arrange controlled storage for a delayed shipment, and avoid the blind spot where product is cleared but no one has told the warehouse to expect it. This connection is precisely why integrated customs brokerage and warehousing is so valuable for pharmaceutical importers.

Release Status and Everything Downstream

Product release status, quarantined, released, or rejected, has to be enforced across the system, not held in one person’s knowledge or one team’s spreadsheet. If the quality team quarantines a lot, that status must prevent the product from being picked and shipped, must be visible to customer service, and must be part of the audit trail. A disconnect here is how quarantined product ships by mistake, which is among the more serious failures a regulated operation can have.

Excursions, Lots, and the Audit Trail

A temperature excursion is only meaningful if it is linked to the specific lots and shipments it affected. An excursion event floating in a monitoring system, unconnected to the product it touched, cannot support a sound disposition decision. Connected data ties the excursion to the lot, the lot to the shipment, and all of it to a complete, retrievable audit trail, so that when a question arises about a specific product, the full history is available in one place.

The Client Should See What You See

One of the clearest tests of a connected 3PL is whether the client’s view matches the internal view. When customer reporting draws on the same data as warehouse operations, customs, and quality, the client sees accurate inventory, real shipment status, and true release status, the same reality the provider’s own teams are working from. When customer reporting is a separate, manually assembled view, it drifts from reality, and the gaps show up at the worst times.

For a regulated products client, this transparency is part of the trust that the relationship depends on. The client retains accountability to FDA for their product. Giving them accurate, real-time visibility into its status, drawn from the same connected data the provider uses, is how a logistics partner supports that accountability rather than obscuring it.

How Euro-American Worldwide Logistics Approaches Connected Data

Euro-American Worldwide Logistics operates with a structural advantage in connecting this data: our licensed U.S. Customs Brokerage and our cGMP warehouse operate as one team, in one facility. The customs status of an imported shipment and the warehouse that will receive it are not separate companies exchanging information across a gap. They are the same operation, which means customs status, receiving, inventory, release status, and shipment visibility are coordinated rather than reconciled after the fact.

We offer flexible inventory control that works through our own warehouse management system or integrates with a client’s internal system, with real-time updates and immediate alerts, so clients see accurate, current information rather than a manually assembled snapshot. As the broader logistics industry invests in connecting warehouse, transportation, and customs data, we continue to invest in making sure that, for the regulated products we handle, those functions genuinely tell the same story.

If you want a logistics partner whose customs, warehouse, and shipment data work as a connected whole rather than as separate islands, contact our team today.

---

The Descartes acquisition of Extensiv referenced in this article was announced in early September 2026. This article is an industry perspective provided for informational purposes.

A biotech company rarely sets out to build a logistics strategy. It sets out to develop a therapy. Logistics is something that seems to take care of itself in the early days, a courier here, a cold shipper there, a freight forwarder when something needs to come in from overseas. And for a while, that improvised approach works.

Then the company grows, and at some point the improvisation stops working. A clinical trial needs investigational product delivered to sites on a schedule with an unbroken temperature record. A scale-up requires importing raw materials in volumes that need real storage. A commercial launch demands distribution infrastructure that did not exist the year before. The companies that navigate this progression well are the ones that recognized, early enough, that logistics was going to become a strategic function rather than a series of one-off tasks.

This is a particularly relevant journey in the Massachusetts life sciences ecosystem, where a remarkable density of companies are moving along exactly this path, from research through clinical development, scale-up, manufacturing, and commercial distribution. This article walks through how logistics requirements change at each stage, and when a biotech company should start thinking about logistics as a strategy rather than a task.

Stage 1: Research

In the research stage, logistics needs are real but modest in volume. The company is moving small quantities of high-value materials: reagents, biological samples, specialized research materials, reference standards, and equipment. Much of this is sourced internationally, because the specialized suppliers of research materials are distributed around the world.

The logistics requirements at this stage center on careful handling of small, valuable, often temperature-sensitive shipments, and on the customs considerations that come with importing research materials. Even at this early stage, some materials require import permits, FDA or other agency awareness, and proper classification. A mishandled or delayed inbound shipment of a critical reagent can stall research for weeks. The company may not need a comprehensive logistics strategy yet, but it does benefit from a customs and logistics partner who can handle specialized international inbound shipments reliably.

Stage 2: Clinical

The clinical stage is where logistics requirements take a significant step up in complexity and consequence. Now the company is producing investigational product and delivering it to clinical trial sites, sometimes a handful, sometimes dozens, sometimes across multiple countries. Every shipment carries strict requirements: validated temperature control, complete chain-of-custody documentation, time-critical delivery windows, and the regulatory compliance that governs investigational materials.

stakes change here in a way that is easy to underestimate. A temperature excursion or a delivery failure does not just cost money. It can compromise a patient’s participation in a trial, disrupt a study timeline that represents years of work and enormous investment, and in the worst case, jeopardize the integrity of the trial data itself. Clinical trial logistics demands a level of reliability and documentation discipline that improvised arrangements struggle to provide consistently.

The clinical stage is usually where a biotech company first realizes it needs a logistics strategy, not a logistics vendor. The reliability, documentation, and temperature control required to support a trial are not things you want to be arranging shipment by shipment.

Stage 3: Scale-Up

As a therapy moves toward commercial viability, the company scales up production, and the logistics picture changes character again. The focus shifts toward the inbound supply chain that will feed larger-scale manufacturing: raw materials, active pharmaceutical ingredients, excipients, and packaging components, increasingly in volumes that require real storage rather than just-in-time delivery to a lab.

Scale-up is when several new logistics requirements emerge at once. The company begins importing manufacturing inputs in meaningful quantities, which raises the stakes on customs classification, country-of-origin documentation, and compliant entry. It needs somewhere to store those inputs under appropriate, often temperature-controlled and GMP-compliant, conditions. And it needs to qualify suppliers and the logistics processes that connect them, because a commercial-scale operation cannot depend on a supply chain that has not been validated.

This is also the stage where the cost of fragmentation starts to show. Managing separate relationships for freight forwarding, customs brokerage, and storage, each optimizing for its own piece, creates gaps and inefficiencies that become more expensive as volume grows. The integration of these functions starts to deliver real value.

Stage 4: Manufacturing

At commercial manufacturing scale, logistics is unambiguously a strategic function. The company is now running an ongoing operation that depends on a reliable inbound flow of manufacturing inputs and produces finished product that has to be stored and moved. The supply chain is continuous rather than project-based, and disruptions have direct commercial consequences.

The logistics requirements at this stage are comprehensive. Imported APIs and excipients need compliant customs clearance and validated storage. Safety stock of critical inputs needs to be held to protect against supply disruption. Manufacturing equipment and spare parts need reliable import handling, because a production line down for a missing imported component is an expensive problem. Finished product coming off the line needs GMP-compliant storage and the beginnings of a distribution capability. And all of it needs the documentation and quality-system rigor that a commercial pharmaceutical operation is held to.

Manufacturers at this stage often face a build-versus-outsource decision on storage and logistics infrastructure. Building internal capacity is capital-intensive and slow. Partnering with a qualified GMP logistics provider offers immediate, validated capability, and preserves the company’s capital and management attention for manufacturing itself. This is a stage where the right logistics partnership becomes a genuine competitive advantage.

Stage 5: Commercial Distribution

Commercial launch is the culmination of the journey, and it brings the most demanding logistics requirements of all. Now the company is distributing finished product to market at scale, to wholesalers, distributors, pharmacies, hospitals, or directly to patients, depending on the product and the model. The requirements span cGMP-compliant distribution, validated cold chain for temperature-sensitive products, order fulfillment, final-mile delivery, and returns management, all under continuous quality control and complete documentation.

A commercial launch is also the moment of maximum operational intensity for a company, and the least forgiving time to be building logistics infrastructure from scratch. Product is being manufactured, regulatory milestones are being met, commercial teams are ramping, and the market is waiting. A distribution failure at launch, product that cannot reach the market on time, or reaches it compromised, is among the most damaging outcomes a company can experience after years of development. This is precisely why the logistics strategy needs to be in place before launch, not assembled during it.

The companies that launch smoothly are almost always the ones that treated logistics as a strategic priority well before the launch itself, building the customs, storage, and distribution capability in advance rather than scrambling to assemble it under launch pressure.

When Should a Biotech Company Start Thinking About Logistics Strategy?

The honest answer is: earlier than most companies do. The instinct to treat logistics as a task that can be handled as it arises works in the research stage and starts to strain in the clinical stage. By scale-up, the companies that are still improvising are usually feeling the cost, in delays, in excursions, in fragmented vendor relationships, and in management time consumed by problems that a strategic approach would have prevented.

A practical guideline: a biotech company benefits from establishing a real logistics partnership at the point where its supply chain first becomes consequential to its timeline, which is usually the clinical stage. A partner engaged early can grow with the company through each subsequent stage, so that the customs, storage, and distribution capability the company will need at commercial scale is built on a foundation that already exists and already understands the business, rather than being assembled from scratch under launch pressure.

How Euro-American Worldwide Logistics Supports the Full Journey

Euro-American Worldwide Logistics is built to support life sciences companies across every stage of this progression. Our integrated platform, combining licensed U.S. Customs Brokerage, international freight forwarding, and cGMP-compliant storage and distribution under one roof in Worcester, Massachusetts, means a company can begin working with us for specialized inbound research shipments and continue with us through clinical distribution, scale-up import and storage, commercial manufacturing support, and full commercial distribution.

For the biotech and pharmaceutical companies of the Massachusetts life sciences ecosystem in particular, we offer something valuable: a logistics partner located in the heart of the region, who understands the journey from lab bench to commercial shipment, and who can grow with a company rather than being replaced at each stage. Our white-glove service packages are designed specifically to guide new products from pre-clinical through launch with a dedicated team across customs, logistics, transportation, and storage.

If your company is moving along this path and wants a logistics partner who can support you at your current stage and grow with you into the next, contact our team today.

Why Life Sciences Manufacturers Should Not Read the Oversupply Headlines as Their Story

The cold storage industry is working through an oversupply. After a speculative construction boom that added roughly 14.5% capacity between 2021 and 2025, the sector is now absorbing an estimated 10% oversupply, and capacity growth is decelerating sharply as developers and lenders pull back from new projects. Read on its own, that data suggests temperature-controlled storage is easy to find and getting cheaper.

For a life sciences manufacturer that needs FDA-registered, cGMP-compliant storage for raw materials, work-in-process, or finished product, that reading is misleading. The cold storage oversupply is concentrated in general-purpose refrigerated space, much of it built for food and bulk perishables. Pharmaceutical-grade storage is a different market with different economics, and within the broader cold storage sector, pharmaceutical cold chain is consistently identified as the fastest-growing demand segment, not an oversupplied one.

A manufacturer who reads “cold storage is oversupplied” and assumes validated pharmaceutical capacity will be easy to secure is reading the wrong segment of the market. General refrigerated space and cGMP-compliant pharmaceutical storage are not interchangeable, and the forces loosening one are not loosening the other.

Two Markets That Get Reported as One

Cold storage tends to be discussed as a single category in industry coverage and real estate reporting. In practice, it splits into segments with very different supply and demand dynamics, and the gap between them matters enormously for a life sciences manufacturer trying to plan capacity.

The oversupply that dominates recent headlines is concentrated in general-purpose cold storage: the large refrigerated and frozen warehouses that serve food processing, grocery distribution, and bulk perishables. That segment saw heavy speculative construction during the pandemic years, and it is now working through the resulting excess. Frozen storage alone accounts for roughly half of total cold storage demand, and much of the new speculative capacity was built for exactly that kind of high-volume, food-oriented use.

Pharmaceutical-grade storage is a fundamentally different product. It requires FDA registration, cGMP-compliant quality systems, validated temperature zones, continuous monitoring, audit-ready documentation, and often security certifications like CTPAT. A food-grade frozen warehouse with empty pallet positions does not meet those requirements, and it cannot be casually converted to meet them. The oversupply in one segment does very little to ease capacity in the other.

Why Pharmaceutical Storage Demand Keeps Rising

While general cold storage absorbs its oversupply, the demand drivers for pharmaceutical-grade storage continue to strengthen. Several forces are converging:

Biologics and Specialty Medicine Pipeline

The pharmaceutical pipeline has shifted decisively toward biologics, cell and gene therapies, and other specialty medicines that require refrigerated or frozen storage throughout the supply chain. The gene, cell, and RNA therapy pipeline reached thousands of therapies in development as of 2025, and specialty medicines are projected to account for a growing majority of new drug launches. Nearly all of these products require validated cold chain storage that general refrigerated space cannot provide.

The GLP-1 Surge

The explosive growth of GLP-1 medications for diabetes and weight management has created substantial new demand for pharmaceutical-grade refrigerated storage and handling. These are temperature-sensitive biologics produced and distributed at enormous scale, and they require cold chain infrastructure that meets pharmaceutical, not food-grade, standards.

Reshoring and Domestic Manufacturing

The wave of U.S. pharmaceutical manufacturing investment now underway is generating new domestic demand for validated raw-material and finished-product storage. As more pharmaceutical production happens on U.S. soil, the need for compliant warehousing to stage imported inputs and hold finished product grows alongside it.

Supply Resilience and Safety Stock

The supply chain disruptions of recent years have made pharmaceutical companies more willing to hold safety stock of critical products and inputs. That strategic inventory requires validated storage capacity, adding to demand that is structural rather than temporary.

The Risk of Misreading the Market

The practical danger for a life sciences manufacturer is straightforward. A company that reads the cold storage oversupply headlines and concludes that validated pharmaceutical storage will be readily available, and cheap, when it needs it may delay a capacity decision that should be made proactively. Then, when a production ramp, a commercial launch, or an inventory surge creates an urgent need, the specific validated, FDA-registered, cGMP-compliant space required may not be available in the right location on the timeline the business needs.

Validated pharmaceutical storage cannot be stood up overnight. Whether a manufacturer builds it internally or secures it through a qualified partner, the process of qualifying space, validating temperature zones, and establishing compliant quality systems takes time. A general-purpose cold storage glut provides no cushion against that reality, because the empty space in the glut is the wrong kind of space.

The headline that matters for a life sciences manufacturer is not “cold storage is oversupplied.” It is “pharmaceutical-grade cold chain is the fastest-growing demand segment.” Those two facts are both true at the same time, and only the second one describes the market a manufacturer actually operates in.

What Life Sciences Manufacturers Should Do

Given the gap between the general cold storage picture and the pharmaceutical-grade reality, a few practical priorities follow for manufacturers planning their storage strategy:

• Plan capacity against pharmaceutical-grade supply, not general cold storage headlines. The oversupply in food-grade space is irrelevant to your validated storage needs
• Decide proactively, not reactively. Secure validated storage capacity before a production ramp or launch forces an urgent decision, when options are fewer and timelines are tighter
• Evaluate qualified partners early. A relationship with an FDA-registered, cGMP-compliant storage partner can provide capacity faster than building internally, but the qualification process still takes time to do properly
• Weigh location alongside capacity. Validated space in the wrong region adds transit time and freight cost. Proximity to your manufacturing and distribution footprint matters
• Confirm the specifics, not just the label. “Temperature-controlled” is not the same as validated cGMP storage. Confirm FDA registration, validated zones, monitoring, and documentation

How Euro-American Worldwide Logistics Fits

Euro-American Worldwide Logistics operates a 45,000 square foot FDA-registered, cGMP-compliant facility in Worcester, Massachusetts, with 25,000 square feet of dual temperature-controlled refrigeration supporting validated 2 to 8 degrees C and 15 to 25 degrees C storage. This is pharmaceutical-grade storage built and maintained for FDA-regulated products, not general cold storage repurposed for pharmaceutical use.

For life sciences manufacturers in the Northeast evaluating storage capacity, whether for raw material staging, safety stock, overflow, or finished-product distribution, we provide validated storage with continuous monitoring, ISO-9001 certified quality systems, CTPAT-certified security, and the integrated customs brokerage and freight forwarding that support internationally sourced materials. And we are positioned centrally in the Massachusetts life sciences corridor, close to the manufacturers and research institutions we serve.

If you are planning your pharmaceutical storage strategy and want to talk through validated capacity that fits your requirements and timeline, contact our team today.

---

Sources include Westside Construction Group analysis of the 2026 cold storage construction cycle; Future Market Insights and DataM Intelligence cold chain market data; GCCA Cold Facts 2026 outlook; and American Society of Gene & Cell Therapy pipeline data. Market figures reflect the cited sources and span differing methodologies and time horizons.

The headlines are striking. Reuters reported in August 2026 that major global pharmaceutical companies have announced more than $500 billion in combined U.S. manufacturing, research, and supply chain investment commitments. The list of companies is a who’s who of the industry: Pfizer, Eli Lilly, Johnson & Johnson, Roche, AstraZeneca, Novartis, Merck, Amgen, AbbVie, Gilead, Sanofi, and others. At the same time, FDA is actively promoting domestic manufacturing capacity through programs such as FDA PreCheck, designed to streamline the regulatory readiness of new U.S. drug manufacturing facilities.

It is tempting to read this as a simple story: pharmaceutical manufacturing is coming back to America, and international logistics matters less as a result. That reading is wrong, and for any company whose supply chain touches pharmaceutical manufacturing, understanding why it is wrong is worth some attention.

A few important caveats about the headline number itself. The $500 billion figure spans very different time horizons, and should not be read as $500 billion of immediate construction. Tariff exposure is one factor driving these commitments, alongside supply security, market access, pricing agreements, and broader manufacturing strategy. And critically, building a pharmaceutical plant in the United States does not make that plant independent of international supply chains. In many cases, it creates entirely new international logistics demand.

Reshoring does not eliminate international logistics. It changes the logistics. A new U.S. pharmaceutical plant can still depend heavily on imported ingredients, equipment, and materials, and it generates new domestic warehousing and distribution requirements that did not exist before.

1. Finished-Drug Imports Versus Raw-Material Imports

The reshoring narrative focuses on finished drug manufacturing: the plants that produce the tablets, vials, and injectables that reach patients. Moving that final production step to the United States does reduce finished drug imports over time. But finished drug production is the last stage of a long supply chain, and the stages before it remain heavily international.

A U.S. plant that manufactures a finished biologic or small molecule drug still needs active pharmaceutical ingredients, excipients, and packaging to do so. If those inputs are imported, and for most U.S. pharmaceutical production today they substantially are, then the reshoring of finished manufacturing has shifted the composition of pharmaceutical imports rather than eliminating them. Fewer finished drugs cross the border. More raw materials and components do.

2. APIs and Excipient Sourcing

The active pharmaceutical ingredient is the heart of any drug, and API manufacturing is one of the most globally concentrated segments of the entire pharmaceutical supply chain. A large share of global API production, and an even larger share of the key starting materials that feed API synthesis, is concentrated in China and India. That concentration does not disappear because a finished drug plant opens in Virginia or Massachusetts.

In fact, a new domestic finished-drug facility often increases API import demand at its point of entry, because that facility needs a reliable, compliant, well-documented inbound flow of API to operate. The same applies to excipients, the binders, fillers, stabilizers, and delivery agents that make up the non-active portion of a finished drug. Many specialized excipients are produced by a small number of international suppliers, and a U.S. plant depends on importing them regardless of where the final drug is made.

For the logistics function, this means the reshoring trend is generating demand for exactly the capabilities that support compliant pharmaceutical importing: customs brokerage, FDA-coordinated entry, temperature-controlled handling for sensitive inputs, and validated storage of incoming raw materials.

3. Equipment and Spare-Parts Logistics

Building a pharmaceutical manufacturing facility requires pharmaceutical manufacturing equipment, and much of the world’s specialized bioprocessing and fill-finish equipment is built outside the United States. Bioreactors, chromatography systems, isolators, fill-finish lines, and process analytical technology are frequently manufactured in Europe and elsewhere, then imported, installed, and qualified in the new U.S. facility.

This creates a distinct and time-sensitive logistics requirement during the construction and commissioning phase of every reshoring project. High-value, often oversized, and sometimes sensitive equipment must be imported, cleared through customs, and delivered on a schedule that aligns with facility construction milestones. A customs delay on a critical piece of equipment can push back a facility qualification timeline by weeks.

The requirement does not end when the facility opens. Imported manufacturing equipment needs imported spare parts, and it needs them on demand. A production line down for want of a replacement component sourced from an overseas manufacturer is an expensive problem. Reliable, fast import handling for spare parts is an ongoing logistics need that begins the day the plant becomes operational and continues for the life of the equipment.

4. GMP Raw-Material Warehousing

A domestic pharmaceutical plant that depends on imported APIs, excipients, and components needs somewhere to store those materials under compliant conditions. Raw materials for pharmaceutical manufacturing frequently require validated temperature control, controlled humidity, segregation, and full chain-of-custody documentation, the same cGMP standards that apply to finished product.

Manufacturers often do not want to build all of that raw-material storage capacity inside the manufacturing facility itself, where floor space is expensive and dedicated to production. Staging imported raw materials at a nearby GMP-compliant warehouse, then feeding them into the plant on a just-in-time or scheduled basis, is an efficient model that preserves manufacturing floor space and provides an inventory buffer against supply disruptions. That is a direct, growing demand for exactly the kind of validated GMP warehousing that supports a manufacturing operation.

5. Supplier Diversification

The same forces driving pharmaceutical reshoring, supply security concerns, tariff exposure, and geopolitical risk, are also driving supplier diversification for the inputs that reshored plants depend on. A manufacturer building a new U.S. facility to reduce its dependence on foreign finished-drug production is often simultaneously working to diversify the sources of its APIs and raw materials, moving away from single-country concentration.

Supplier diversification multiplies logistics complexity. Sourcing an API from three countries instead of one means three sets of customs entries, three country-of-origin determinations, three sets of supplier documentation, and three inbound freight relationships to manage. The reshoring of finished manufacturing and the diversification of upstream sourcing are happening together, and both increase, rather than decrease, the demand for sophisticated customs and logistics expertise.

6. Safety-Stock Strategy

One of the central motivations behind pharmaceutical reshoring is supply security, the desire to avoid the shortages and disruptions that occur when a critical medicine depends on a fragile, distant, single-source supply chain. But supply security is not achieved by domestic manufacturing alone. It is achieved by holding appropriate safety stock of critical inputs and finished product.

A manufacturer serious about supply resilience will carry buffer inventory of imported APIs and critical raw materials, precisely so that a disruption in international supply does not halt domestic production. That safety stock has to be stored somewhere, under compliant conditions, with accurate inventory management and full documentation. The reshoring trend, properly understood, increases the demand for validated warehousing capacity to hold the strategic inventory that makes domestic production resilient.

7. Customs Planning for Manufacturing Inputs

a company imports finished drugs, its customs activity is relatively straightforward: a defined set of finished products, classified and entered on a predictable basis. When that same company shifts to domestic manufacturing that relies on imported inputs, its customs profile becomes more complex, not less.

Now the company is importing APIs, excipients, packaging components, equipment, and spare parts, each with its own HTS classification, its own regulatory requirements, and its own entry considerations. Some inputs may face Section 232 pharmaceutical tariffs depending on classification and origin. Some may qualify for exemptions. Country-of-origin determinations become more numerous and more consequential. The customs planning required to support a domestic manufacturing operation is substantially more involved than the customs planning required to simply import a finished product.

This is a critical and often underappreciated point. Reshoring finished manufacturing does not simplify a company’s customs footprint. It transforms it into a more complex, higher-volume, more varied set of import activities that require ongoing customs brokerage expertise to manage compliantly.

8. Distribution Requirements Once Domestic Production Begins

Finally, a domestic pharmaceutical plant does not just receive inputs. It produces finished product that has to be distributed. Once a U.S. facility begins commercial production, it generates demand for finished-product warehousing, temperature-controlled distribution, order fulfillment, and final-mile delivery, all under cGMP conditions and all within the United States.

This is domestic logistics demand that did not exist when the product was manufactured abroad and imported in finished form. The reshoring of manufacturing creates a new domestic distribution requirement at the output end of the plant, just as it creates new import requirements at the input end. Both are logistics demand, and both are growing as the reshoring investments move from announcement to operation.

The Bigger Picture: A Different Logistics Map, Not a Smaller One

The table below summarizes the categories of international and domestic logistics demand that pharmaceutical reshoring generates, rather than eliminates.

The reshoring of pharmaceutical manufacturing is real, and it is significant. But it is not the end of pharmaceutical logistics complexity. It is a redrawing of the map. The flows change. Finished-drug imports decline over time, while imports of APIs, excipients, equipment, and spare parts rise. New domestic warehousing and distribution requirements emerge. Customs activity becomes more complex, not less. Supplier diversification multiplies the number of relationships to manage.

For pharmaceutical manufacturers, the practical implication is that a domestic manufacturing strategy needs a logistics strategy to match, one that accounts for compliant importing of manufacturing inputs, GMP-compliant raw-material and finished-product warehousing, sophisticated customs planning, and domestic distribution capability.

How Euro-American Worldwide Logistics Supports Reshored Manufacturing

Euro-American Worldwide Logistics is built for exactly the logistics profile that pharmaceutical reshoring creates. Our integrated platform combines licensed U.S. Customs Brokerage, international freight forwarding, and cGMP-compliant warehousing under one roof in Worcester, Massachusetts, at the center of one of the most active life sciences manufacturing regions in the country.

For a manufacturer importing APIs, excipients, packaging, equipment, or spare parts to support U.S. production, our customs brokerage team manages the classification, entry, and compliance requirements, while our validated cGMP warehouse provides the temperature-controlled staging and safety-stock storage that a resilient manufacturing operation depends on. For finished product coming off a domestic line, we provide the compliant warehousing and distribution to move it to market.

If your organization is building or expanding U.S. pharmaceutical manufacturing capacity and wants a logistics partner who understands that reshoring changes logistics rather than eliminating it, contact our team today.

---

Sources include Reuters reporting on pharmaceutical U.S. investment commitments (August 2026); company investment announcements from AstraZeneca, Eli Lilly, Johnson & Johnson, Pfizer, Merck, and others; and FDA materials on the PreCheck program for domestic manufacturing facilities. Investment figures span multiple time horizons and should not be read as immediate construction spending.

On July 13, 2026, FDA updated the import alert covering drugs and medical devices from firms without valid registration and listing. FDA’s import alert database is updated in real time, and products identified under this alert may be subject to detention without physical examination, meaning the shipment is held automatically at the port of entry without FDA needing to test or physically inspect it first.

An update to this alert does not necessarily represent a new agency-wide policy. Updates of this kind routinely add or remove individual firms or products and revise alert information as FDA’s records change. But the update is a useful prompt to revisit a phrase that appears constantly in supplier qualification conversations and rarely gets defined precisely: FDA registered.

For pharmaceutical, biotech, and medical device importers, that phrase is doing more work in casual conversation than it can actually support as a compliance verification. This article breaks down what FDA registration actually confirms, what it does not, and what a complete import readiness verification should include.

Why This Matters Operationally: A freight forwarder, customs broker, or GMP warehouse cannot correct a deficient establishment registration after the shipment reaches the border. At that point, the logistics problem becomes detention, controlled storage, demurrage, and the management of a temperature-sensitive product’s remaining shelf life while the underlying compliance issue is resolved.

Six Distinct Compliance Concepts Hiding Behind One Phrase

When a supplier, a sales contact, or a commercial invoice describes a product as FDA registered, that statement can be referring to any one of several distinct regulatory concepts, and importers frequently assume it covers more ground than it does. The table below separates these concepts and shows why confirming one does not confirm the others.

Establishment registration is a precondition to admissibility. It is not, by itself, evidence that a specific shipment is compliant, correctly listed, properly authorized, free of import alert exposure, or accurately declared on the entry.

Why the July 13 Update Is a Useful Prompt

Import alerts covering unregistered or unlisted firms exist precisely because registration and listing status can change, and because FDA’s compliance database reflects real-time additions and removals. A manufacturer that was properly registered when a supplier relationship began can lose that status. A product that was correctly listed can fall out of compliance if the establishment’s registration lapses or the listing is not maintained.

This means supplier verification is not a one-time event that happens during initial qualification. It is an ongoing verification that should be repeated at intervals, and certainly before any shipment moves, particularly for suppliers or products that have not shipped recently.

A commercial invoice or a supplier’s written assurance that a facility is FDA registered reflects the supplier’s understanding of their own status. It does not reflect a current, independent check against FDA’s own records at the time of shipment.

What a Complete Import Readiness Verification Includes

Before a regulated shipment departs, importers should independently verify the following, rather than relying on supplier representations alone:

1. Verify the actual manufacturing establishment, not just the name on the commercial invoice.
2. Confirm the establishment’s current registration status directly against FDA records.
3. Confirm the exact product listing tied to that registered establishment.
4. Confirm the party identified on FDA entry data matches the actual manufacturer.
5. Check whether the manufacturer or the specific product is implicated by an active import alert.

Each of these checks is available through FDA’s own public databases and systems, and a licensed customs broker with pharmaceutical and device experience should be conducting this verification as a routine part of pre-shipment compliance review, not as a special request reserved for higher-risk suppliers.

Why the Party on FDA Entry Data Matters

One verification step deserves particular attention because it is easy to overlook. The entity identified on the electronic entry data submitted to FDA through CBP’s Automated Commercial Environment must correctly identify the actual manufacturing establishment, using that establishment’s correct registration number. If the wrong establishment is identified, whether due to a data entry error, an outdated record, or confusion between a manufacturer and a distributor or trading company, the entry itself can be flagged for review even when the actual product and actual manufacturer are both properly registered and compliant.

This is a documentary error, not a product quality issue, and it illustrates why establishment registration status alone is an incomplete check. A product can come from a fully compliant, registered manufacturer and still be detained because the entry data submitted at the border does not correctly reflect that fact.

What Happens When Verification Is Skipped

When a registration or listing deficiency is discovered only after a shipment reaches a U.S. port, the available remedies are limited and none of them are fast. The importer may need to demonstrate compliance after the fact, which can require documentation from the foreign establishment that takes time to assemble. The product sits in detention, or in controlled storage if the importer can arrange it, while the issue is resolved. Demurrage and storage costs accrue. For a temperature-sensitive product, every day in detention consumes shelf life that cannot be recovered.

None of this can be fixed by the logistics function alone. A freight forwarder can expedite transportation. A customs broker can file an accurate entry. A GMP warehouse can hold a detained product under validated conditions while the issue is worked through. None of them can retroactively create a valid establishment registration or product listing that did not exist at the time of shipment. The verification has to happen before the product leaves the origin country, not after it arrives.

How Euro-American Worldwide Logistics Supports Supplier Verification

Euro-American Worldwide Logistics’ licensed U.S. Customs Brokerage conducts establishment registration and product listing verification as a standard part of pre-shipment compliance review for pharmaceutical, biologic, and medical device clients. Our team checks the manufacturing establishment identified on shipping documentation against FDA’s registration and listing records, confirms the product is correctly listed, and reviews current import alert status before a shipment moves, not after it is held at the port.

For clients working with new suppliers, or reviewing an existing supplier relationship after a period without shipments, we can perform this verification as part of supplier qualification, well before the first commercial shipment is scheduled.

If you would like to review your current supplier verification practices or have a specific shipment you want checked before it departs, contact our team today.

---

This article references FDA’s import alert publication record and the July 13, 2026 update to the alert covering unregistered or unlisted drug and device firms. Import alert status should be verified directly against FDA’s current records before shipment.